The absence of SOX2 amplification in a series of in vivo pure EC and EC containing mixed nonseminomas, suggest that SOX2 oncogene dependence, at least due to gene amplification, is not a frequent mechanism in GCC, which questions indeed the approach of targeted therapy in a clinical setting. Here, SOX2 is linked to goblet cell carcinoma.